Taletrectinib 200 mg Suppliers & Bulk Manufacturers

Available Forms: Capsules

Available Strengths: 200 mg

Reference Brands: Ibtrozi (USA)

Category: Oncology Cancer Care

Taletrectinib is a next-generation tyrosine kinase inhibitor that targets ROS1 and NTRK fusion proteins. It is used to treat adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer. It works by blocking the abnormal ROS1 signaling that drives cancer cell growth and proliferation. Because it is taken once daily, on an empty stomach (2 hours before or after food), it has specific administration requirements.

Product Description:

Taletrectinib inhibits ROS1 and TRK kinases, and was developed to address the two problems that limit the older ROS1 drugs: resistance mutations at the solvent front, and off-target inhibition of TRKB in the brain, which produces the dizziness and gait disturbance that lead patients to reduce or stop treatment. Greater selectivity for ROS1 over TRKB is intended to preserve efficacy while sparing those central effects.

It is used for locally advanced or metastatic ROS1-positive non-small cell lung cancer, both in previously untreated patients and after a prior ROS1 inhibitor, with activity against the G2032R resistance mutation and against brain metastases. It is taken once daily on an empty stomach, two hours away from food, which is a real adherence consideration. Transaminase elevation is frequent and requires liver monitoring; diarrhoea, nausea and vomiting are common, usually early and manageable.

Sourcing notes. Recently approved originator product, on patent, with registration so far in a limited number of territories — verify before quoting. Requires ROS1 fusion testing at the destination, generally by next-generation sequencing. Small but growing patient population with long treatment duration. Oral capsules, room temperature.